Equities researchers at StockNews.com began coverage on shares of Quotient (NASDAQ:QTNT – Get Rating) in a research report issued to clients and investors on Sunday. The firm set a "hold" rating on the stock.
A number of other equities analysts have also issued reports on the stock. BTIG Research decreased their target price on shares of Quotient from $9.00 to $1.50 and set a "buy" rating for the company in a research report on Wednesday, June 29th. Cowen decreased their target price on shares of Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a research report on Wednesday, June 29th. Finally, Cowen decreased their target price on shares of Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a research report on Wednesday, June 29th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $2.25.
Get Quotient alerts:Quotient Stock Performance
Quotient stock opened at $0.17 on Friday. The company has a 50-day simple moving average of $0.22 and a 200-day simple moving average of $0.47. The firm has a market capitalization of $17.89 million, a P/E ratio of -0.13 and a beta of 2.76. Quotient has a one year low of $0.16 and a one year high of $3.19.
Quotient (NASDAQ:QTNT – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The firm had revenue of $8.81 million for the quarter, compared to analyst estimates of $9.40 million. As a group, sell-side analysts forecast that Quotient will post -0.69 earnings per share for the current year.Insider Activity
In other Quotient news, Director Prondzynski Heino Von acquired 700,000 shares of Quotient stock in a transaction dated Thursday, September 15th. The stock was bought at an average price of $0.20 per share, for a total transaction of $140,000.00. Following the transaction, the director now owns 1,405,879 shares in the company, valued at approximately $281,175.80. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders acquired 984,808 shares of company stock worth $195,354. Corporate insiders own 10.50% of the company's stock.
Hedge Funds Weigh In On Quotient
Several large investors have recently made changes to their positions in the business. Walleye Capital LLC boosted its position in shares of Quotient by 4,136.3% during the 2nd quarter. Walleye Capital LLC now owns 3,000,000 shares of the company's stock valued at $720,000 after purchasing an additional 2,929,184 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Quotient in the second quarter worth about $343,000. JPMorgan Chase & Co. boosted its holdings in shares of Quotient by 9,156.7% in the second quarter. JPMorgan Chase & Co. now owns 3,491,154 shares of the company's stock worth $838,000 after buying an additional 3,453,439 shares during the period. State Street Corp boosted its holdings in shares of Quotient by 8.1% in the first quarter. State Street Corp now owns 1,502,911 shares of the company's stock worth $1,803,000 after buying an additional 112,013 shares during the period. Finally, Clearbridge Investments LLC boosted its holdings in shares of Quotient by 0.8% in the first quarter. Clearbridge Investments LLC now owns 4,255,908 shares of the company's stock worth $5,107,000 after buying an additional 33,409 shares during the period. Institutional investors own 86.84% of the company's stock.
About Quotient
(Get Rating)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.
Featured Stories
- Get a free copy of the StockNews.com research report on Quotient (QTNT)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.